Heidi Liljenbäck

Heidi Liljenbäck

Auto-generated profile, based on publicly available information

Heidi Liljenbäck

Turku PET Centre, University of Turku, Turku University Hospital, Turku, Finland

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Cell Metabolism
Verified
Journal Article
Closed access
JNJoni Nikkanen
Joni Nikkanen
SFSaara Forsström
Saara Forsström
LELiliya Euro
Liliya Euro
IPIlse Paetau
Ilse Paetau
RKRebecca A. Kohnz
Rebecca A. Kohnz
ASAnu Suomalainen
Anu Suomalainen

1 December 2019 in Cell Metabolism
Verified
Journal Article
Closed access
SFSaara Forsström
Saara Forsström
CJChristopher B. Jackson
Christopher B. Jackson
CCChristopher J. Carroll
Christopher J. Carroll
MKMervi Kuronen
Mervi Kuronen
EPEija Pirinen
Eija Pirinen
ASAnu Suomalainen
Anu Suomalainen

16 October 2012 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
JMJorma A. Määttä
Jorma A. Määttä
KBKalman G. Büki
Kalman G. Büki
GGGuoliang Gu
Guoliang Gu
MAMaria H. Alanne
Maria H. Alanne
JVJukka Vääräniemi
Jukka Vääräniemi
KVKalervo Väänänen
Kalervo Väänänen
The role of the estrogen receptor α (ERα) in bone‐forming cells is incompletely understood at present. To examine the in vivo effects of ERα in these cells, we generated a mouse strain in which the ERα gene is inactivated in osteoblasts via osteocalcin promoter‐regulated cyclic recombinase (Cre) activity (ERα ΔOB/ΔOB ). This enabled micro‐computed tomography‐ and histomorphometry‐based analysis of ERα‐mediated effects in bone‐forming cells in mice, in which the systemic ERα‐mediated effects are intact. In female ERα ΔOB/ΔOB mice, trabecular and cortical bone volumes were significantly reduced (31.5 and 11.4%, respectively) at 3.5 mo of age compared with control ERα fl/fl animals, and their response to ovariectomy was small compared with that of controls. In contrast with females, no differences could be detected in the bone phenotype of young males, whereas in 6‐mo‐old ERα ΔOB/ΔOB males, trabecular bone volume (Tb.BV) was decreased (27.5%). The ERα inactivation‐related effects were compared with those of controls having a similar genetic background. Parental osteocalcin‐Cre mice did not show Cre‐related changes. Our results suggest that in female mice, Tb.BV and cortical bone volume are critically dependent on the ERα regulation of osteoblasts, whereas in male mice, osteoblastic ERα is not required for the regulation of bone formation during rapid skeletal growth, but it is involved in the maintenance of Tb.BV.—Määttä, J. A., Büki, K. G., Gu, G., Alanne, M. H., Vääräniemi, J., Liljenbäck, H., Poutanen, M., Härkönen, P., Väänänen, K. Inactivation of estrogen receptor α in bone‐forming cells induces bone loss in female mice. FASEB J. 27, 478–488 (2013). www.fasebj.org

14 April 2023 in The American Journal of Human Genetics
Verified
Journal Article
Open access
TÖTiit Örd
Tiit Örd
TLTapio Lönnberg
Tapio Lönnberg
VNValtteri Nurminen
Valtteri Nurminen
ARAarthi Ravindran
Aarthi Ravindran
HNHenri Niskanen
Henri Niskanen
MKMinna U Kaikkonen
Minna U Kaikkonen
Coronary artery disease (CAD) is a pandemic disease where up to half of the risk is explained by genetic factors. Advanced insights into the genetic basis of CAD require deeper understanding of the contributions of different cell types, molecular pathways, and genes to disease heritability. Here, we investigate the biological diversity of atherosclerosis-associated cell states and interrogate their contribution to the genetic risk of CAD by using single-cell and bulk RNA sequencing (RNA-seq) of mouse and human lesions. We identified 12 disease-associated cell states that we characterized further by gene set functional profiling, ligand-receptor prediction, and transcription factor inference. Importantly, Vcam1+ smooth muscle cell state genes contributed most to SNP-based heritability of CAD. In line with this, genetic variants near smooth muscle cell state genes and regulatory elements explained the largest fraction of CAD-risk variance between individuals. Using this information for variant prioritization, we derived a hybrid polygenic risk score (PRS) that demonstrated improved performance over a classical PRS. Our results provide insights into the biological mechanisms associated with CAD risk, which could make a promising contribution to precision medicine and tailored therapeutic interventions in the future.

6 January 2017 in ACS Omega
Verified
Journal Article
Open access
OKOuti Keinänen
Outi Keinänen
EMErmei M. Mäkilä
Ermei M. Mäkilä
RLRici Lindgren
Rici Lindgren
HVHelena Virtanen
Helena Virtanen
HLHeidi Liljenbäck
Heidi Liljenbäck
AAAnu J. Airaksinen
Anu J. Airaksinen
Pretargeted positron emission tomography (PET) imaging based on bioorthogonal chemical reactions has proven its potential in immunoimaging. It may also have great potential in nanotheranostic applications. Here, we report the first successful pretargeted PET imaging of trans-cyclooctene-modified mesoporous silicon nanoparticles, using 18F-labeled tetrazine as a tracer. The inverse electron-demand Diels–Alder cycloaddition (IEDDA) reaction was fast, resulting in high radioactivity accumulation in the expected organs within 10 min after the administration of the tracer. The highest target-to-background ratio was achieved 120 min after the tracer injection. A clear correlation between the efficiency of the in vivo IEDDA labeling reaction and the injected amount of the tracer was observed. The radioactivity accumulation decreased with the increased amount of the co-injected carrier, indicating saturation in the reaction sites. This finding was supported by the in vitro results. Our study suggests that pretargeted imaging has excellent potential in nanotheranostic PET imaging when using high-specific-activity tracers.

26 June 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JSJohanna M. U. Silvola
Johanna M. U. Silvola
Xiang-Guo LiXiang-Guo Li
Xiang-Guo Li
JVJenni Virta
Jenni Virta
PMPäivi Marjamäki
Päivi Marjamäki
HLHeidi Liljenbäck
Heidi Liljenbäck
Anne RoivainenAnne Roivainen
Anne Roivainen
Inflammation plays an important role in the development of atherosclerosis and its complications. Because the folate receptor β (FR-β) is selectively expressed on macrophages, an FR targeted imaging agent could be useful for assessment of atherosclerotic inflammation. We investigated aluminum fluoride-18-labeled 1,4,7-triazacyclononane-1,4,7-triacetic acid conjugated folate (18F-FOL) for the detection of atherosclerotic plaque inflammation. We studied atherosclerotic plaques in mice, rabbits, and human tissue samples using 18F-FOL positron emission tomography/computed tomography (PET/CT). Compound 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) was used as a comparison. Firstly, we found that the in vitro binding of 18F-FOL co-localized with FR-β-positive macrophages in carotid endarterectomy samples from patients with recent ischemic symptoms. We then demonstrated specific accumulation of intravenously administered 18F-FOL in atherosclerotic plaques in mice and rabbits using PET/CT. We noticed that the 18F-FOL uptake correlated with the density of macrophages in plaques and provided a target-to-background ratio as high as 18F-FDG, but with considerably lower myocardial uptake. Thus, 18F-FOL PET/CT targeting of FR-β-positive macrophages presents a promising new tool for the in vivo imaging of atherosclerotic inflammation.